A systematic review and meta-analysis of selected toxicity endpoints of alpelisib.

ABSTRACT:

Purpose

Alpelisib is a first-in-class α-specific phosphatidylinositol 3-kinase inhibitor approved for the treatment of patients with estrogen receptor-positive metastatic breast cancer. High absolute risk (AR) of relevant toxicities has been observed with this treatment. This meta-analysis aimed to improve the precision of the estimated AR of selected adverse events (AEs) associated with this new agent.

Materials and methods

A literature search was conducted in August 2019 to identify trials analyzing the anti-tumor efficacy and toxicity profile of alpelisib. Heterogeneity was assessed by using I ² statistics. Data were analyzed using random effect meta-analyses for AR. Eleven trials and 511 patients were included.

Results

There was no evidence of he

SUBMITTER: Shields M 

PROVIDER: S-EPMC7584237 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature